冠心病痰浊证研究进展

Research Progress in Phlegm Syndrome of Coronary Heart Diseases

痰浊证作为冠心病主要证候,除临床症状体征明确,还与相关基因多态性、血浆代谢组学、蛋白质代谢组学、尿液代谢组学等指标有一定对应关系,其中血脂指标与冠心病痰浊证关系密切,进一步研究可作为证候诊断的依据,并指导临床治疗,为中医证候学走向国际化提供了良好的基础。本文基于相关研究,认为中医治疗冠心病应在化痰基础上注重痰瘀同治,注意控制血脂指标,以此提高临床疗效,并期望在目前尚未建立的冠心病痰浊证疗效评价系统方面进行深入研究。

Phlegm syndrome, as the main syndrome of coronary heart diseases, not only its clinical signs and symptoms are clear, but also related with gene polymorphism, plasma metabolomics, genomics protein metabolism and urine metabolomics indicators, especially the close connection between serum lipids and phlegm syndrome in coronary heart diseases. The further research on the connection can be used as the references for the syndrome diagnosis and clinical treatment guidance, and provide solid foundation for TCM syndromes toward internationalization. This article pointed out that the treatment of coronary heart diseases should retain Chinese characteristics, focus on the basis of the phlegm syndrome, and pay attention to control lipid levels, in order to improve the clinical efficacy, and look forward to making progress in in-depth study on efficacy evaluation system of phlegm syndrome in coronary heart diseases.